Lineage Cell Therapeutics, Inc. (LCTX) stock
Close on Nov 11, 2026Market cap $280.73MP/E –Yield –
Lineage Cell Therapeutics, Inc. grew revenue 19.9% to $13.08M over the twelve months to Jun 30, 2026. Free cash flow was -$24.39M. At the latest close the market valued the company at $280.73M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $280.73M
- P/E ratio
- –
- Price to sales
- 21.46
- Price to book
- 4.61
- Dividend yield
- –
- Free cash flow yield
- -8.69%
Fundamentals
- Revenue
- $13.08M
- Net income
- -$32.26M
- EPS, diluted
- -$0.19
- Free cash flow
- -$24.39M
- Book value per share
- $0.23
- Diluted shares
- 261M
Trading
- Next earnings
- Q3 FY2026, expected soon
- Previous close
- $1.04
- Open
- $1.03
- Day's range
- $1.00 – $1.13
- Volume
- 1,716,832
- Average volume (20 days)
- 1,308,023
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.99
- 52-week range
- $0.88 – $1.99
- RSI (14 days)
- 61.6
- Volatility (1 year)
- 55.2%
- Relative volume
- 1.42×
- WACC
- 9.8%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | LCTX | S&P 500 | Difference | LCTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +11.7% | -2.4% | +14.1 pts | ||
| 3 months | -0.9% | -1.2% | +0.3 pts | ||
| Year to date | -33.5% | +12.3% | −45.8 pts | ||
| 1 year | -39.0% | +12.4% | −51.5 pts | ||
| 3 years | +6.7% | +78.8% | −72.1 pts | +2.2% | +21.4% |
| 5 years | -54.9% | +75.2% | −130.0 pts | -14.7% | +11.9% |
| 10 years | -69.2% | +311.1% | −380.3 pts | -11.1% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Lineage Cell Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
About Lineage Cell Therapeutics
Biological Products, (No Diagnostic Substances)
Lineage is a clinical-stage biotechnology company that develops allogeneic cell replacement therapies to treat serious degenerative conditions and traumatic injuries. Utilizing its proprietary AlloSCOPE manufacturing platform, the company differentiates pluripotent stem cells into specific, functional replacement cells designed to restore lost cellular activity. Its clinical-stage pipeline features OpRegen for geographic atrophy secondary to dry age-related macular degeneration and OPC1 for spinal cord injuries, alongside preclinical candidates such as ReSonance for auditory neuropathy. The company develops these off-the-shelf therapies for patients with cellular loss or impairment, providing ready-to-use formulations for administration by medical specialists such as retinal surgeons.
Company profile, executives and historyLineage Cell Therapeutics stock: common questions
What is Lineage Cell Therapeutics's stock price?
LCTX closed at $1.11 on Nov 11, 2026, up 6.73% on the day. Over the past 52 weeks it traded between $0.88 and $1.99.
What is Lineage Cell Therapeutics's market cap?
Lineage Cell Therapeutics was worth $280.73M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is LCTX's P/E ratio?
Lineage Cell Therapeutics lost money over the twelve months to Jun 30, 2026 (diluted EPS -$0.19), so it has no meaningful P/E ratio.
How much revenue does Lineage Cell Therapeutics make?
Lineage Cell Therapeutics reported revenue of $13.08M for the twelve months to Jun 30, 2026, up 19.9% from a year earlier.
Does Lineage Cell Therapeutics pay a dividend?
No. Lineage Cell Therapeutics has not paid a cash dividend over the last twelve months.
When does Lineage Cell Therapeutics report earnings next?
Lineage Cell Therapeutics's Q3 FY2026 results are due soon; the company has not yet filed them with the SEC.
How has LCTX stock performed over the past year?
Including dividends, LCTX returned -39.0% over the past year, against +12.4% for the S&P 500.
How many LCTX shares are sold short?
24M shares were sold short at the latest FINRA report, 37.66% of the float, or 19.3 days of average trading volume.
Who are Lineage Cell Therapeutics's competitors?
Companies most similar to Lineage Cell Therapeutics by business, industry and size include CRBU, ISCO, OCGN, FATE, ZEOX.
See a number that looks wrong?